Verification evidence is still being completed.
PDF / print export
AB2 Bio Ltd.
Lausanne, Switzerland
- Verified lead
- Djordje Filipovic
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- IL-18 Therapeutics, Tadekinig Alfa, and Phase 3 Autoinflammatory Disease Development
- Review cycle
- 24 April 2026
- Full address
- EPFL Innovation Park, 1015 Lausanne, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- AB2 Bio leadership team page naming Djordje Filipovic as Chief Executive Officer.
- Editorial note
- EPFL Lausanne Phase 3 clinical-stage autoinflammatory-disease biotech with named CEO, Tadekinig alfa program, and 650 million USD Nippon Shinyaku partnership.
IL-18 Therapeutics, Tadekinig Alfa, and Phase 3 Autoinflammatory Disease Development
Phase 3 clinical program, Nippon Shinyaku commercialization partnership, Public CEO disclosure
EPFL Lausanne Phase 3 clinical-stage autoinflammatory-disease biotech with named CEO, Tadekinig alfa program, and 650 million USD Nippon Shinyaku partnership.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Lausanne, Switzerland
AB2 Bio Ltd.
IL-18 Therapeutics, Tadekinig Alfa, and Phase 3 Autoinflammatory Disease Development · Phase 3 clinical biologics development
EPFL Lausanne Phase 3 clinical-stage autoinflammatory-disease biotech with named CEO, Tadekinig alfa program, and 650 million USD Nippon Shinyaku partnership.
- Lead
- Djordje Filipovic (verified ↗)
- Address
- EPFL Innovation Park, 1015 Lausanne, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Phase 3 clinical biologics development
- Capabilities
- IL-18 Therapeutic Development · Tadekinig Alfa Phase 3 Program · US and International Commercialization Partnerships
- Founded
- 2000
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED APRIL 2026
Djordje Filipovic
Chief Executive Officer
Full addressEPFL Innovation Park, 1015 Lausanne, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
AB2 Bio homepage listing the EPFL Innovation Park Lausanne headquarters.
Open sourcePhase 3 clinical biologics development
Lausanne, Switzerland. IL-18 Therapeutics, Tadekinig Alfa, and Phase 3 Autoinflammatory Disease Development. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for clinical oversight
Phase 3 clinical program, Nippon Shinyaku commercialization partnership, Public CEO disclosure
IL-18 Therapeutics, Tadekinig Alfa, and Phase 3 Autoinflammatory Disease Development
EPFL Lausanne Phase 3 clinical-stage autoinflammatory-disease biotech with named CEO, Tadekinig alfa program, and 650 million USD Nippon Shinyaku partnership.
Editorial note
AB2 Bio is a Phase 3 clinical-stage Lausanne biotech with a named CEO, a Tadekinig alfa program for IL-18 driven HLH and rare diseases, and a disclosed 650 million USD Nippon Shinyaku partnership for US commercialization.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
IL-18 Therapeutic Development
Tadekinig Alfa Phase 3 Program
US and International Commercialization Partnerships
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
IL-18 biologics development
Clinical trial operations
Partner CDMO supply
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is AB2 Bio Ltd. located?
- AB2 Bio Ltd. operates from EPFL Innovation Park, 1015 Lausanne, Switzerland, Lausanne, Switzerland.
- Who runs AB2 Bio Ltd.?
- AB2 Bio Ltd. is led by Djordje Filipovic, Chief Executive Officer. Verified 24 Apr 2026.
- What does AB2 Bio Ltd. do?
- EPFL Lausanne Phase 3 clinical-stage autoinflammatory-disease biotech with named CEO, Tadekinig alfa program, and 650 million USD Nippon Shinyaku partnership. Core capabilities: IL-18 Therapeutic Development, Tadekinig Alfa Phase 3 Program, US and International Commercialization Partnerships.
Editorial context
Related technical briefs
Briefs that name Lausanne as a covered market or city.